Lind Jennifer N, Interrante Julia D, Ailes Elizabeth C, Gilboa Suzanne M, Khan Sara, Frey Meghan T, Dawson April L, Honein Margaret A, Dowling Nicole F, Razzaghi Hilda, Creanga Andreea A, Broussard Cheryl S
Division of Congenital and Developmental Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia;
US Public Health Service, Atlanta, Georgia.
Pediatrics. 2017 Jun;139(6). doi: 10.1542/peds.2016-4131.
Opioid use and abuse have increased dramatically in recent years, particularly among women.
We conducted a systematic review to evaluate the association between prenatal opioid use and congenital malformations.
We searched Medline and Embase for studies published from 1946 to 2016 and reviewed reference lists to identify additional relevant studies.
We included studies that were full-text journal articles and reported the results of original epidemiologic research on prenatal opioid exposure and congenital malformations. We assessed study eligibility in multiple phases using a standardized, duplicate review process.
Data on study characteristics, opioid exposure, timing of exposure during pregnancy, congenital malformations (collectively or as individual subtypes), length of follow-up, and main findings were extracted from eligible studies.
Of the 68 studies that met our inclusion criteria, 46 had an unexposed comparison group; of those, 30 performed statistical tests to measure associations between maternal opioid use during pregnancy and congenital malformations. Seventeen of these (10 of 12 case-control and 7 of 18 cohort studies) documented statistically significant positive associations. Among the case-control studies, associations with oral clefts and ventricular septal defects/atrial septal defects were the most frequently reported specific malformations. Among the cohort studies, clubfoot was the most frequently reported specific malformation.
Variabilities in study design, poor study quality, and weaknesses with outcome and exposure measurement.
Uncertainty remains regarding the teratogenicity of opioids; a careful assessment of risks and benefits is warranted when considering opioid treatment for women of reproductive age.
近年来,阿片类药物的使用和滥用显著增加,尤其是在女性中。
我们进行了一项系统综述,以评估产前阿片类药物使用与先天性畸形之间的关联。
我们检索了1946年至2016年发表在Medline和Embase上的研究,并查阅了参考文献列表以识别其他相关研究。
我们纳入了全文期刊文章形式的研究,并报告了关于产前阿片类药物暴露与先天性畸形的原始流行病学研究结果。我们使用标准化的重复审查流程在多个阶段评估研究的合格性。
从符合条件的研究中提取有关研究特征、阿片类药物暴露、孕期暴露时间、先天性畸形(总体或作为个体亚型)、随访时间和主要发现的数据。
在符合我们纳入标准的68项研究中,46项有未暴露的对照组;其中,30项进行了统计检验以衡量孕期母亲使用阿片类药物与先天性畸形之间的关联。其中17项(12项病例对照研究中的10项和18项队列研究中的7项)记录了具有统计学意义的正相关。在病例对照研究中,与腭裂和室间隔缺损/房间隔缺损的关联是最常报告的特定畸形。在队列研究中,马蹄内翻足是最常报告的特定畸形。
研究设计的差异、研究质量差以及结局和暴露测量方面的不足。
关于阿片类药物的致畸性仍存在不确定性;在考虑对育龄妇女进行阿片类药物治疗时,有必要仔细评估风险和益处。